Abbott Laboratories (Pakistan) Limited Stock

Equities

ABOT

PK0025701019

Pharmaceuticals

End-of-day quote Pakistan S.E. 06:00:00 2024-04-14 pm EDT 5-day change 1st Jan Change
530 PKR -2.81% Intraday chart for Abbott Laboratories (Pakistan) Limited +1.22% +15.16%
Sales 2022 49.26B 177M Sales 2023 55.48B 200M Capitalization 45.05B 162M
Net income 2022 3B 10.82M Net income 2023 262M 943K EV / Sales 2022 0.75 x
Net cash position 2022 8.54B 30.77M Net cash position 2023 4.88B 17.57M EV / Sales 2023 0.72 x
P/E ratio 2022
15.1 x
P/E ratio 2023
172 x
Employees 1,430
Yield 2022
3.24%
Yield 2023
-
Free-Float 16.36%
More Fundamentals * Assessed data
Dynamic Chart
Abbott Laboratories Limited Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Abbott Laboratories Limited Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
Abbott Laboratories Limited Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 CI
Abbott Laboratories Limited Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
Abbott Laboratories Limited Reports Earnings Results for the Full Year Ended December 31, 2022 CI
Abbott Laboratories Limited Reports Earnings Results for the Full Year Ended December 31, 2022 CI
Abbott Laboratories Limited Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022 CI
Abbott Laboratories Limited Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022 CI
Abbott Laboratories Announces Board Changes CI
Abbott Laboratories Limited Reports Earnings Results for the First Quarter Ended March 31, 2022 CI
Abbott Laboratories Limited Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2021 CI
Abbott Laboratories Pakistan Limited Reports Earnings Results for the Second Quarter Ended June 30, 2021 CI
Abbott Laboratories Pakistan Limited Reports Earnings Results for the First Quarter Ended March 31, 2021 CI
Abbott Laboratories Limited Reports Earnings Results for the Full Year Ended December 31, 2020 CI
Abbott Laboratories Pakistan Limited Reports Earnings Results for the Third Quarter Ended September 30, 2020 CI
More news
1 day-2.81%
1 week+6.14%
Current month+10.69%
1 month+16.08%
3 months+16.48%
6 months+40.31%
Current year+15.16%
More quotes
1 week
527.23
Extreme 527.23
553.85
1 month
440.00
Extreme 440
553.85
Current year
399.99
Extreme 399.99
553.85
1 year
330.00
Extreme 330
553.85
3 years
330.00
Extreme 330
820.00
5 years
302.10
Extreme 302.1
820.00
10 years
302.10
Extreme 302.1
1 145.00
More quotes
Managers TitleAgeSince
Chief Executive Officer - 09-02-28
Director of Finance/CFO - 20-01-15
Chief Operating Officer - -
Members of the board TitleAgeSince
Chairman - -
Chief Executive Officer - 09-02-28
Director/Board Member - -
More insiders
Date Price Change Volume
24-04-15 530 -2.81% 6,700
24-04-09 545.3 +4.14% 72,900

End-of-day quote Pakistan S.E., April 14, 2024

More quotes
Abbott Laboratories Pakistan Limited is engaged in the manufacture, import and marketing of branded generic pharmaceutical, nutritional, diagnostic, diabetes care, molecular devices, hospital and consumer products. The Company operates through four segments: Pharmaceutical, Nutritional, Diagnostic, and Others. It offers treatment options for a number of areas, including the digestive system, heart health, women’s health, respiratory illness, central nervous system/pain and influenza vaccines. Its nutritional brands include Similac, PediaSure, Pedialyte, Ensure, and Glucerna. It offers tests and diagnostic tools, medical diagnostic instruments, automation and informatics solutions for hospitals, reference labs, blood centers, emergency departments, physician offices and clinics. The Company’s easy-to-use test strips require only tiny blood samples while its meters provide results and reports.
More about the company